Therapeutics, Inc. holder reports 8.22% stake
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Therapeutics, Inc. (par value $0.001 per share, CUSIP 359616109).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reports beneficial ownership of common stock of Therapeutics, Inc. (par value $0.001 per share, CUSIP 359616109).
As of June 30, 2026, the reporting persons may be deemed beneficial owners of 5,475,040 shares, representing 8.22% of the outstanding common stock. These shares are held by funds and separately managed accounts under Nantahala’s control. Each reporting person has shared voting power and shared dispositive power over 5,475,040 shares and no sole voting or dispositive power. Harkey and Mack file as control persons with respect to shares beneficially owned by Nantahala, an investment adviser.
Key Figures
Key Terms
beneficial owner financial
Schedule 13G regulatory
control person financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of FULC common stock does Nantahala Capital Management report owning?
What type of SEC filing is this Schedule 13G for FULC?
Who are the reporting persons in the FULC Schedule 13G filing?
As of what date are the FULC beneficial ownership figures reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.